On Tuesday, Shares of Micron Technology, Inc. (NASDAQ:MU), lost -3.17% to $26.87.
On April 27, Micron Technology, declared the pricing of an offering of $550 million aggregate principal amount of its 5.250% senior notes due 2024 and $450 million aggregate principal amount of its 5.625% senior notes due 2026. The Notes are being offered to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons following Regulation S under the Securities Act. The sale of the Notes is predictable to close on April 30, 2015, subject to the satisfaction of customary closing conditions. Interest on the 2024 Notes will accrue at a rate of 5.250% per year and interest on the 2026 Notes will accrue at a rate of 5.625% per year. Interest on the Notes will be payable in cash semi-annually in arrears, starting on July 15, 2015.
The 2024 Notes will mature on January 15, 2024 and the 2026 Notes will mature on January 15, 2026, unless earlier repurchased or redeemed. Holders may require Micron to repurchase their Notes upon the occurrence of certain change of control events at a repurchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Shares of DIRECTV (NASDAQ:DTV), inclined 1.38% to $90.61, during its last trading session, as the Justice Department and the Federal Communications Commission are said to be close to concluding their review of AT&T’s $49 billion acquisition of DirecTV (DTV), sources told the Wall Street Journal, adding it is unlikely that what could be the largest media deal of the last year will be blocked by regulators.
So far recently, 30.60 million shares of AT&T have exchanged hands as contrast to its average daily volume of 26.05 million shares.
The deal has raised opposition from companies such as Netflix (NFLX), arguing that the deal would give the company the power and incentive to choke its online video competition, the Journal said.
DIRECTV, a digital television entertainment company, engages in the direct-to-home (DTH) business in the United States and Latin America. It acquires, promotes, sells, and distributes digital entertainment programming primarily through satellite to residential and commercial subscribers.
At the end of Tuesday’s trade, Shares of zulily, Inc. (NASDAQ:ZU), lost -2.25% to $13.67.
zulily, declared that Brian Swartz has been designated Senior Vice President and Chief Financial Officer, effective June 1, 2015.
Mr. Swartz brings more than 20 years of operational and financial experience to zulily. For the last six years, Mr. Swartz served as Senior Vice President and Chief Financial Officer of Apollo Education Group, Inc., a private-sector education company, where he assisted build a world class global finance team and also formerly held the roles of Treasurer and Chief Accounting Officer. Mr. Swartz joined Apollo from EaglePicher Incorporated, a technology and industrial products and services company, where he served as its Vice-President and Corporate Controller.
zulily, inc. operates as an online retailer in the United States, Canada, Australia, the United Kingdom, and internationally. The company provides merchandise to moms purchasing for their children, themselves, and their homes. Its merchandise comprises men’s, women’s, and children’s apparel, accessories, and shoes; children’s merchandise, such as infant gear, sports equipment, toys, and books; and other merchandise comprising kitchen accessories, home décor, entertainment, electronics, pet accessories, and health and beauty products.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with 8.24% gain, and closed at $3.68.
On April 30, Exelixis declared that the Exelixis-discovered compounds cabozantinib and cobimetinib will be the subjects of fourteen presentations at the forthcoming 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting, which will be held from May 29 to June 2, 2015 in Chicago, Illinois, is predictable to draw 30,000 oncology professionals from around the world.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
